Aug 11 2026
/
Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient’s life, together, created a widely accepted logic: high prices were simply the cost of innovation.
That exception hasn’t gone away in 2026. But it’s split into two very different stories, and the split matters more than any single “pricing is under pressure” headline.
The Market Hasn’t Slowed Down
Orphan drugs already make up roughly a fifth of total US prescription drug spend. Market projections put the category above $400 billion of the nearly $1.9 trillion in total 2032 prescription drug sales, up from about $217 billion in 2025. On the regulatory side, roughly half of the 46 novel drugs the FDA approved in 2025 carried an orphan designation, and more than 70% moved through an expedited pathway.
That’s not what a category in retreat looks like. Premium pricing in rare disease isn’t eroding across the board; it’s still working. What’s changed is how it’s being protected.
The Legislative Signal: Protection for Narrow Orphan Drugs Actually Got Stronger
Here’s a fact that’s easy to miss: in July 2025, the One Big Beautiful Bill Act amended the IRA’s orphan drug exclusion. Before this, only drugs with a single approved orphan indication were exempt from Medicare price negotiation, so a second orphan approval could actually strip a drug of protection it already had. That penalized companies for developing additional rare-disease uses. The amendment fixed that: orphan drugs can now have multiple rare-disease indications and still keep their exemption, as long as none of those indications is a non-orphan use. That’s a real strengthening of price protection, not a weakening.
But the protection is conditional, and one case makes the boundary clear: ibrutinib (Imbruvica), a drug with orphan and hematologic-malignancy roots, was among the first drugs Medicare negotiated under the IRA, taking a roughly 38% price cut once its label grew beyond narrow orphan use.
Stay narrowly orphan, and the exclusion protects you. Broaden the label, and you’re back in negotiation territory, on the government’s terms.
The Payer Signal: This is Where the Actual Pressure is Coming From
So if statutory protection for genuinely narrow orphan drugs eased in 2025, where’s the squeeze rare disease teams are feeling right now? Almost entirely at the commercial and Medicaid payer level, and it’s a lot more concrete than vague talk of “implicit thresholds.”
The evidence bar is rising. HTA bodies are asking harder questions of thin data packages. A data package built on a small population or a single-arm trial needs to justify itself, not just get a pass because the disease is rare.
Utilization management remains the default tool. Orphan drugs priced above roughly $50,000 a year have long faced disproportionate prior authorization requirements in Medicare Part D, and newer review layers have piled on top of that rather than replaced it.
And outcomes-based contracting has quietly gone from pilot project to real infrastructure. CMS’s Cell and Gene Therapy Access Model, launched in January 2025, has CMS itself negotiating outcomes-based deals with manufacturers, including Bluebird Bio for Lyfgenia, Vertex and CRISPR for Casgevy, on behalf of state Medicaid programs. More than 30 states had signed on by early 2026, making it the largest coordinated outcomes-based contracting push in US history. A separate CMS rule, effective this year, now lets manufacturers report multiple “best prices” when they strike value-based deals with states, removing a barrier that had blocked this kind of arrangement for years. Pfizer has already used it for Beqvez, its hemophilia B gene therapy.
This is the real trade-off layer in 2026: not narrower eligibility in the abstract, but named CMS programs, named manufacturers, and a specific rule change that took effect this year.
What This Means for Launch Strategy
The old playbook: high unmet need plus small population equals pricing freedom, was never entirely true, and two specific dynamics now make that gap obvious:
First, indication strategy is a pricing decision, not just a clinical one. Stay within a defined set of orphan indications, and the amended IRA exclusion protects you. Push into broader or non-orphan use, and that protection starts to slip, as ibrutinib shows.
Second, deal structure isn’t optional anymore for expensive launches. CMS is running outcomes-based agreements at Medicaid scale, and the best-price barrier is gone. A company that shows up at launch without some kind of risk-sharing structure (installment payments, outcomes-based rebates, warranties) is negotiating from a weaker position than one that’s already built a deal.
Evidence strategy still has to anticipate payer and HTA scrutiny before launch, not respond to it afterward. But a good sustainability story isn’t enough on its own anymore. What holds a price up now is indication strategy and deal structure built for the rules as they actually stand today.